3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
3
Glioma
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lipodystrophy, Congenital Generalized
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Astrocytoma
1
Advanced Cancer
1
Interventions
Vincristine
8
Magnetic Resonance Spectroscopy
8
Cyclophosphamide
7
Cisplatin
6
X-Rays
5
Specimen Handling
5
Radiotherapy
5
Phantoms, Imaging
5
Irinotecan
5
Carboplatin
5
Temozolomide
4
Radiation
4
Platinum
4
Nuclear Medicine Department, Hospital
4
Lomustine
4
palbociclib
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Etoposide
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
sonidegib
2
selpercatinib
2
olaparib
2
merphos
2
larotrectinib
2
ivosidenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Medulloblastoma
×
Tetanus Toxoid
×
Clear all
NCT03615404
2021-01-28
ATTAC-P
Duke University
Phase 1
Completed
11 enrolled
7 charts